Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A randomized, double-blind, parallel-group, placebo and active controlled, multi-center dose ranging study with beta-3 agonist YM178 in patients with symptomatic overactive bladder (DRAGON)
mirabegron
178-CL-044
NCT00337090
EudraCT 2005-002256-17
Urinary Bladder, Overactive
Phase 2
 
September 2016

Powered by ideaPoint, Inc.